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Abstract: A simple, speciﬁ  c, sensitive, and rapid high performance liquid chromatography (HPLC) method for the 
determination of griseofulvin in small volumes of rat plasma was developed and validated using warfarin as an internal 
standard. Biological sample preparation involved simple extraction with acetonitrile, followed by dilution with aqueous 
mobile phase buffer (20 mM sodium dihydrogen phosphate, pH 3.5) to eliminate any chromatographic solvent effects. 
Griseofulvin and warfarin were baseline separated and quantitated on a C18 reversed phase column (4.6 × 150 mm, 3.5 μm), 
using a mobile phase composed of a 20 mM aqueous solution of sodium dihydrogen phosphate-acetonitrile (55:45, v/v, pH 3.5) 
delivered at a ﬂ  ow rate of 1.0 mL/min, and with ﬂ  uorescence detection (λexcitation = 300 nm, λemission = 418 nm). The method 
was proven to be linear over a plasma griseofulvin concentration range of 10 to 2500 ng/mL with a mean correlation 
coefﬁ  cient of 0.9996. The intra-day and inter-day accuracy (relative error) were in the range of 0.89% to 9.26% and 0.71% 
to 7.68%, respectively. The within-day precision (coefﬁ  cient of variation) was less than 3.0% and the between-day precision 
was less than 7.5%. The mean recovery of griseofulvin from rat plasma was found to be 99.2%. The limit of detection (LOD) 
and the limit of quantiﬁ  cation (LOQ) of griseofulvin were determined to be 1 ng/mL and 10 ng/mL, respectively. The 
developed method was successfully applied to quantitatively assess the pharmacokinetics of griseofulvin in rats following 
a single 50 mg/kg oral dose of the drug.
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Introduction
Griseofulvin (7-chloro-2’, 4, 6-trimethoxy-6’-methyl-gris-2’-en-3, 4’-dione; Fig. 1) is an oral active 
antifungal antibiotic derived from the mold Penicillium griseofulvum that is primarily used to treat 
dermatophyte infections in humans and animals. Griseofulvin is a poorly water-soluble drug, which 
displays a dissolution rate-limited absorption pattern in humans and animals. Hence, it is often used as 
a model drug to assess the inﬂ  uence of various physicochemical, physiological, and dosage form factors 
on the absorption kinetics and bioavailability of hydrophobic drugs.
A number of analytical methods have been described for the detection of griseofulvin in biological 
ﬂ  uids (e.g. spectroﬂ  uorometry [1, 2], gas chromatography (GC) [3–5], thin-layer chromatography [6], 
high performance liquid chromatography (HPLC) [6–10], and liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) [11]). Reported spectroﬂ  uorometric methods [1, 2] are sensitive, but lack 
the required speciﬁ  city. GC methods [3–5] with electron capture detection showed high sensitivity and 
speciﬁ  city, but require a derivatization procedure and sample preparation is lengthy. Previously devel-
oped HPLC methods with ﬂ  uorescence detection have such disadvantages as low selectivity [8], large 
sample size volume [9], and lack of an internal standard [6, 7, 10]. The recently reported electrospray 
ionization LC-MS/MS method [11] for griseofulvin in human plasma has high speciﬁ  city and sensitiv-
ity, but the instrumentation is expensive, and it requires solid phase extraction of the drug. In addition, 
there is a paucity of information in the literature on the analysis of griseofulvin in rat plasma with req-
uisite sensitivity and selectivity for preclinical pharmacokinetic studies.
The present report describes a simple, speciﬁ  c, sensitive, and rapid HPLC method with ﬂ  uorescence 
detection to determine griseofulvin in small volumes of rat plasma. The method involves a single step 
acetonitrile extraction of griseofulvin from rat plasma. The limits of detection (LOD) and quantiﬁ  cation 
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(LOQ) are greatly improved compared to other 
reported HPLC methods for griseofulvin in 
biological media [7–10] and are comparable to 
the LC/MS/MS method of Mistri and co-
workers [11].
Experimental
Chemicals and Reagents
Griseofulvin and warfarin sodium, were purchased 
from Sigma (St. Louis, MO, U.S.A). Acetonitrile 
(HPLC grade), phosphoric acid (85%, HPLC 
grade), and sodium dihydrogen phosphate mono-
hydrate (reagent grade) were obtained from Fisher 
Scientiﬁ  c (Fair Lawn, NJ, U.S.A). All reagents 
were used as received. Double deionized water was 
generated by a Milli-Q
® academic ultra-pure 
water puriﬁ  cation system (Millipore, Bedford, 
MA, U.S.A).
Preparation of Standards and Plasma 
Samples
Stock solutions of griseofulvin (200 μg/mL) and 
the internal standard (IS) warfarin (200 μg/mL) 
were individually prepared in acetonitrile. Ten 
working standard solutions containing 0.10, 0.25, 
0.50, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0 μg/mL of 
griseofulvin were prepared by further dilution of 
the griseofulvin stock solution with appropriate 
volumes of acetonitrile. A working solution of the 
internal standard was prepared by diluting the stock 
solution of warfarin with acetonitrile to give a ﬁ  nal 
concentration of 50 μg/mL. All stock solutions 
were stored at 4 ºC and all working solutions were 
freshly prepared daily.
Blank plasma was obtained from untreated rats 
and spiked with griseofulvin standard solutions to 
yield calibration standards in plasma at concentrations 
of 10, 25, 50, 100, 250, 500, 1000, 1500, 2000, 
2500 ng/mL. Mobile phase buffer (0.02 M aqueous 
solution of sodium dihydrogen phosphate, adjusted 
to pH 3.5 with phosphoric acid) was spiked with 
griseofulvin standard solutions to obtain calibration 
standards in buffer at concentrations of 10, 25, 50, 
100, 250, 500, 1000, 1500, 2000, 2500 ng/mL. Qual-
ity control (QC) standards (n = 8) were also prepared 
by spiking blank plasma with appropriate volumes of 
griseofulvin standard solutions to make low, medium 
and high drug concentrations of 50, 750, 1500 ng/mL, 
respectively.
Each griseofulvin-containing rat plasma sample 
(100 μL) was extracted and deproteinized by mixing 
it with 100 μL of IS working solution containing 
50 μg of warfarin per mL of acetonitrile. The mixture 
was brieﬂ  y vortex-mixed for 10 sec and centrifuged 
at 13,000 rpm for 4 min. A 100 μL aliquot of the 
supernatant was subsequently diluted with 100 μL 
of mobile phase buffer. The resultant solution was 
then vortex-mixed for 10 sec, centrifuged at 13,000 
rpm for 4 min, and a 50 μL aliquot of the supernatant 
was directly injected onto the HPLC column.
Chromatographic Conditions
Chromatographic separations were performed using 
isocratic elutions at ambient temperature. The Waters 
HPLC system (Waters Corporation, Milford, MA, 
U.S.A) consisted of a model 515 pump, a model 717 
plus autosampler, a model 474 scanning ﬂ  uorescence 
detector, and a computer running Waters Empower 
3.2 software. The mobile phase was composed of a 
mixture of 20 mM aqueous sodium dihydrogen 
phosphate solution and acetonitrile (55:45, v/v). The 
ﬁ  nal pH of the mobile phase was adjusted to 3.5 with 
phosphoric acid. The mobile phase was ﬁ  ltered 
through a 0.45 μm GHP membrane ﬁ  lter (Waters 
Corporation, Milford, MA, U.S.A) and degassed 
before use. Griseofulvin and the IS were separated 
on a reversed phase XTerra
® MS C18 column 
(4.6 × 150 mm, 3.5 μm) equipped with an XTerra
® 
MS C18 guard column (3.9 × 20 mm, 3.5 μm). The 
ﬂ  ow rate was set at 1.0 mL/min and the injection 
volume was 50 μL. Griseofulvin and IS ﬂ  uorescence 
measurements were made at excitation and emission 
wavelengths of 300 nm and 418 nm, respectively.
Assay Validation
Linear calibration curves for griseofulvin in rat plasma 
and in buffer were constructed daily by plotting the 
O
O
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Figure 1. Chemical structure of griseofulvin (C17 H17 ClO6).
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peak area ratio of griseofulvin to IS versus known 
griseofulvin plasma or buffer concentrations over the 
range of 10 to 2500 ng/mL.
To validate the assay, three standard calibra-
tion curves of griseofulvin in plasma were 
constructed on the same day to obtain the 
within-day variation. Another two standard cali-
bration curves of griseofulvin in plasma were 
constructed on two separate days to establish the 
between-day variation. Within-day and between-
day accuracy and precision were assessed by 
analyzing quality control (QC) samples at low, 
medium and high griseofulvin concentration 
levels (50, 750, and 1500 ng/mL) in eight repli-
cates on three separate days. Analytical accuracy 
was expressed as the relative percentage error 
(R.E.) from the theoretical drug concentrations 
of QC samples. Analytical precision was reﬂ  ected 
by the coefﬁ  cient of variation (C.V.) associated 
with the mean observed QC concentration at the 
low, medium and high griseofulvin concentration 
levels.
The extraction recovery of griseofulvin from 
rat plasma was estimated from the percentage ratio 
of the slope of the calibration curve in plasma to 
the slope of the calibration curve in buffer (n = 3). 
The limit of detection (LOD) was expressed as the 
plasma concentration that yielded a peak height 
equal to three times that of baseline noise. The 
limit of quantiﬁ  cation (LOQ) was expressed as 
the lowest concentration in the linear calibration 
curve.
The HPLC peak purity of griseofulvin in 
dosed rat plasma was tested by comparing the 
ﬂ  uorescence (F) to UV peak area response ratios 
(F/UV PARR) observed with in vivo griseofulvin-
dosed rat plasma samples to the ratios obtained 
with reference griseofulvin-spiked buffer sam-
ples. The excitation and emission wavelengths 
used for ﬂ  uorescence detection were 300 nm and 
418 nm, respectively, and the UV detection 
wavelength was 291 nm. The in vivo plasma 
samples were obtained at 60 and 90 min after 
administration of a 50 mg/kg oral dose of gris-
eofulvin to Sprague-Dawley rats. Any plasma 
constituent or griseofulvin metabolite that co-
eluted with griseofulvin in the dosed rat plasma 
samples would be expected to alter the F/UV 
PARR from that of the reference griseofulvin-
spiked buffer solutions. Differences between any 
two mean values were statistically evaluated 
using the Student’s t-test.
Pharmacokinetic Studies
The applicability of the developed HPLC method 
for griseofulvin in rat plasma was demonstrated 
by the results obtained from pharmacokinetic stud-
ies conducted in six male Sprague-Dawley rats 
(250 g–350 g). Jugular-vein cannulated, adult male 
rats were fasted 20 hr before and for a 12 hr period 
after griseofulvin dosing. Each rat received an oral 
dose of 50 mg/kg of griseofulvin as an aqueous 
suspension containing 10 mg/mL of griseofulvin 
and 10 mg/mL of polysorbate 80. Water was 
allowed ad libitum. Serial blood samples (0.20 mL) 
were collected from the jugular vein cannula before 
and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hr after 
drug administration. The blood samples were cen-
trifuged at 13,000 rpm for 4 min, and plasma 
samples obtained therefrom were stored at −80 °C 
until analyzed for drug content. Plasma drug 
concentration-time data were subjected to noncom-
partmental pharmacokinetic analyses using the 
nonlinear regression microcomputer program, 
WinNonlin (version 2.1; Pharsight Corporation, 
Mountain View, CA, U.S.A).
Results
Chromatography
The chromatographic peak for griseofulvin and the 
IS from an aqueous buffer solution occurred at 
5.8 min and 9.4 min, respectively (Fig. 2A). No 
significant interfering chromatographic peaks 
appeared for processed blank normal rat plasma 
samples (Fig. 2B). A processed blank rat plasma 
sample spiked with griseofulvin (500 ng/mL) and 
the IS (50 μg/mL) showed baseline separation 
without any interference from endogenous plasma 
constituents (Fig. 2C). The chromatogram for a 
processed plasma sample obtained from a rat 5 hr 
after receiving a 50 mg/kg oral griseofulvin dose 
(Fig. 2D) showed a chromatographic separation 
similar to that of spiked rat plasma (Fig. 2C). The 
total analysis time for each chromatographic run 
was 11 min.
The mean F/UV PARR for the griseofulvin 
orally dosed rat plasma samples (mean ratio + SD 
= 76.7 + 2.9; n = 4) was statistically not different 
(P  0.05) from that of the reference griseofulvin-
spiked buffer samples (mean ratio + SD = 75.1 + 
1.9; n = 6). Thus, the griseofulvin peak obtained 
with dosed rat plasma that eluted at 5.8 min 106
Wei et al
Analytical Chemistry Insights 2008:3
F l o u r e s c e n c e   ( m V )
F l o u r e s c e n c e   ( m V )
F l o u r e s c e n c e   ( m V )
F l o u r e s c e n c e   ( m V )
Time (min)
Time (min)
Time (min)
Time (min)
A
B
C
D 300
250
200
150
100
50
0
300
200
100
0
400
300
200
100
0
100
80
60
40
20
0
0 1 2345678 9 10 11
0 1 2 345678 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2345678 9 10 11
1
2
2
2
1
1107
Development and validation of a HPLC method to determine griseofulvin in rat plasma
Analytical Chemistry Insights 2008:3
was pure without any interference from endogenous 
substances or griseofulvin metabolites.
Linearity and Range
An excellent linear relationship was established 
between the griseofulvin to IS peak area ratio and 
griseofulvin plasma concentration over the 
concentration range of 10 to 2500 ng/mL. The 
concentration range chosen for these calibration 
curves was based on timed plasma griseofulvin 
concentrations expected in planned in vivo oral 
and intravenous animal pharmacokinetic studies. 
Five linear calibration curves for griseofulvin in 
rat plasma were constructed on three separate 
days [day 1 (n = 3), day 2 (n = 1), and day 
3 (n = 1)]. The slope and intercept of each cali-
bration curve was calculated by weighted least 
squares linear regression, and the mean values 
yielded the following mean linear equation: y = 
0.00202 (± 0.000186)* x + 0.0166 (± 0.0440) 
[where y = griseofulvin: IS peak area ratio and 
x = plasma griseofulvin concentration (ng/mL)]. 
The correlation coefﬁ  cient for such linear plots 
ranged from 0.9993 to 0.9998 with a mean value 
of 0.9996. The within-day and between-day 
variations in the slope value were small as 
reﬂ  ected by coefﬁ  cients of variation of 2.17% 
and 2.07%, respectively.
Figure 2. Representative HPLC Chromatograms for (A) a standard buffer solution spiked with griseofulvin (500 ng/mL) and the IS (warfarin; 
50 μg/mL); (B) blank rat plasma; (C) blank rat plasma spiked with griseofulvin (500 ng/mL) and the IS (50 μg/mL); (D) rat plasma sample 
obtained 5 hr after a 50 mg/kg oral dose of griseofulvin; (E) Limit of detection (LOD) of griseofulvin in rat plasma: 1 ng/mL; and (F) Limit of 
quantiﬁ  cation (LOQ) of griseofulvin in rat plasma: 10 ng/mL. Peak 1 = griseofulvin and Peak 2 = IS.
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Accuracy and Precision
The within-day and between-day precision and 
accuracy of the HPLC assay for griseofulvin in 
rat plasma were excellent. The intra-day and 
inter-day accuracy (relative error) were in the 
range of 0.89% to 9.26% and 0.71% to 7.68%, 
respectively. The within-day precision (coefﬁ  -
cient of variation) was less than 3.0% and the 
between-day precision was less than 7.5%.
Limit of Detection and Limit 
of Quantiﬁ  cation
The limit of detection of griseofulvin in rat plasma 
was 1 ng/mL (Fig. 2E) and the limit of quantiﬁ  ca-
tion was 10 ng/mL (Fig. 2F).
Recovery
The mean extraction recovery of griseofulvin from 
rat plasma was 99.2 ± 0.06% (n = 3), indicating 
that insigniﬁ  cant amounts of griseofulvin are lost 
during the plasma protein precipitation step with 
acetonitrile.
Application of the HPLC Method 
to Pharmacokinetic Studies
The proposed HPLC method was successfully 
applied to monitor quantitatively the time course 
of plasma griseofulvin concentrations after oral 
administration of a single 50 mg/kg dose of the 
antibiotic to six adult male Sprague-Dawley rats. 
The mean plasma drug concentration-time proﬁ  le 
observed in these pharmacokinetics studies is 
shown in Figure 3. The following mean (± SD; n 
= 6) noncompartmental pharmacokinetic param-
eters were derived from these data: maximum 
griseofulvin plasma concentration (Cmax) = 981 ± 
308 ng/mL; time of occurrence of Cmax (Tmax) = 
3.33 ± 0.58 hr; total area under the griseofulvin 
plasma concentration-time curve (AUC) = 9.67 ± 
4.9 mg·hr/L; terminal phase elimination half life 
(T1/2) = 4.30 ± 0.42 hr; apparent volume of distri-
bution divided by the fraction of the oral dose 
absorbed (Vd/F) = 41.4 ± 22.5 L; total body 
clearance divided by the fraction of the oral dose 
absorbed (CL/F) = 6.65 ± 3.35 L/hr; and the mean 
residence time of griseofulvin in the body (MRT) = 
8.14 ± 1.14 hr.
Discussion
The present HPLC method has several advan-
tages, such as a small sample size requirement, 
ease of sample preparation, and high sensitivity 
and selectivity, as compared with previously 
published chromatography assays [1–10]. Our 
HPLC method with ﬂ  uorescence detection has 
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Figure 3. Mean plasma concentration–time proﬁ  le of griseofulvin (ng/mL) following an oral dose of 50 mg/kg to six Sprague-Dawley rats.109
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signiﬁ  cantly improved selectivity and limit of 
quantiﬁ  cation (10 ng/mL) ten times lower than 
previously reported HPLC ﬂ  uorescence assays 
for griseofulvin in rat plasma [8], which is crucial 
for pharmacokinetic characterization of drug 
elimination in vivo.
Plasma sample preparation involves single-step 
extraction of plasma with acetonitrile, followed by 
centrifugation and dilution of the supernatant with 
mobile phase buffer before injection onto the 
HPLC column. We found this buffer dilution step 
necessary for optimal chromatography.
Our assay with fluorescence detection is 
comparable to the published LC/MS/MS method 
[11] in terms of linearity, accuracy and precision, 
and it has a better rate of drug recovery. Considering 
the high operational cost and availability of a LC/
MS/MS instrument, our HPLC method with 
ﬂ  uorescence detection appears best suited for pre-
clinical pharmacokinetic studies.
Conclusions
A simple, rapid, speciﬁ  c, sensitive and reproducible 
HPLC method for the quantitative determination 
of griseofulvin in small volumes of rat plasma has 
been developed and validated. The method is 
suitable for studying the oral and intravenous 
pharmacokinetics of griseofulvin using the rat as 
an animal model. It is currently being employed 
in our laboratory to study the effect of simulated 
weightlessness on the absorption and disposition 
kinetics of griseofulvin in the well-established 
tail-suspended rat model for microgravity.
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